Patrick Burnett, MD, PhD

Chief Medical Officer
Arcutis Biotherapeutics, Inc.

Poster(s):

• (101) Improvement in atopic dermatitis signs and symptoms with once-daily and proactive twice-weekly roflumilast cream 0.15% or 0.05%: results from the 52-week phase 3 INTEGUMENT-OLE trial in patients aged ≥2 years
  Wednesday, October 29, 2025

• (103) Efficacy and safety of roflumilast foam 0.3% in patients with psoriasis of the scalp and body in the phase 3 ARRECTOR trial
  Wednesday, October 29, 2025